FDA Broadens Indication for Verzenio (abemaciclib) in HR+, HER2-, Node-Positive, High Risk Early Breast Cancer

INDIANAPOLIS, March 3, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) approved an expanded indication for Verzenio (abemaciclib), in combination with endocrine therapy (ET),...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news